

Resource Summary Report

Generated by [NIF](#) on Sep 7, 2026

HCC1171

RRID:CVCL_5126

Type: Cell Line

Proper Citation

RRID:CVCL_5126

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_5126

Proper Citation: RRID:CVCL_5126

Description: Cell line HCC1171 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Lung adenocarcinoma

Defining Citation: [PMID:9559342](#), [PMID:10353731](#), [PMID:10987304](#), [PMID:20679594](#), [PMID:22460905](#), [PMID:22961666](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26361996](#), [PMID:26589293](#), [PMID:29681454](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31803961](#)

Comments: Miscellaneous: Direct author submission of STR profile from Girard, Luc & Gazdar, Adi F., Population: Caucasian., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: HCC1171

Synonyms: HCC-1171, Hamon Cancer Center 1171

Cross References: BTO:BTO_0006028, EFO:EFO_0003126, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, BioSample:SAMN03473217, BioSample:SAMN10987756, cancercellines:CVCL_5126, Cell_Model_Passport:SIDM01553, Cosmic:903635, Cosmic:909908, Cosmic:1146924, DepMap:ACH-000578, EGA:EGAS00001000610, GEO:GSM108857, GEO:GSM108858, GEO:GSM253406, GEO:GSM434258, GEO:GSM794384, GEO:GSM817118, GEO:GSM887034, GEO:GSM888104, IARC_TP53:11447, IGRhCellID:HCC1171GEO,

KCLB:71171, LiGeA:CCL_622, PharmacDB:HCC1171_446_2019, PRIDE:PXD002556, Progenetix:CVCL_5126, Wikidata:Q54881534

ID: CVCL_5126

Record Creation Time: 20220427T220317+0000

Record Last Update: 20260905T180216+0000

Ratings and Alerts

No rating or validation information has been found for HCC1171.

No alerts have been found for HCC1171.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 2 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Stern YE, et al. (2026) Targeting CDK12/13 Drives Mitotic Arrest to Overcome Resistance to KRASG12C Inhibitors. Cancer research, 86(2), 485.

Janes MR, et al. (2018) Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor. Cell, 172(3), 578.